ExCellThera_RGB.png
ExCellThera announces completion of Phase 2 clinical trials for UM171-expanded cell therapy in high-risk blood cancers
November 15, 2022 08:32 ET | ExCellThera
MONTREAL, Nov. 15, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today the completion of patient enrollment in its...
ExCellThera_RGB.png
ExCellThera announces 100th patient treated with UM171-expanded cell therapy
November 08, 2022 08:35 ET | ExCellThera
MONTREAL, Nov. 08, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today that its proprietary ECT-001 Cell Therapy...
ExCellThera_RGB.png
ExCellThera announces oral presentation of new data on UM171-expanded cell therapy at the ASH Annual Meeting
November 04, 2022 09:30 ET | ExCellThera
MONTREAL, Nov. 04, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today that an abstract related to ExCellThera’s...
ExCellThera_RGB.png
ExCellThera announces submission of Drug Master File for UM171
June 17, 2022 08:05 ET | ExCellThera
MONTRÉAL, June 17, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), an advanced clinical-stage biotechnology company delivering molecules and bioengineering solutions to expand and...
ExCellThera_RGB.png
ExCellThera announces new publication showing its ECT-001 cell therapy improves transplant access for all patients
April 13, 2022 08:05 ET | ExCellThera
MONTREAL, April 13, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), an advanced clinical-stage biotechnology company delivering molecules and bioengineering solutions to expand and engineer...
ExCellThera_RGB.png
ExCellThera announces new data to be presented at the EBMT 2022 annual meeting
March 15, 2022 08:04 ET | ExCellThera
MONTRÉAL, March 15, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a clinical-stage cell expansion and engineering company delivering molecules and bioengineering solutions to expand...
ExCellThera_RGB.png
ExCellThera announces first patient treated in Phase I/II trial of ECT-001 cell therapy for pediatric patients with high risk blood cancer
March 10, 2022 08:04 ET | ExCellThera
MONTREAL, March 10, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a clinical-stage cell expansion and engineering company delivering molecules and bioengineering solutions to expand and...
ExCellThera_RGB.png
ExCellThera announces settlement of its patent infringement claims against Selleck Chemicals
December 21, 2021 08:05 ET | ExCellThera
MONTRÉAL, Dec. 21, 2021 (GLOBE NEWSWIRE) -- ExCellThera Inc., a clinical-stage cell expansion and engineering company delivering molecules and bioengineering solutions to expand and engineer...
ExCellThera_RGB.png
ExCellThera announces data to be presented at the American Society of Hematology 2021 annual meeting
November 29, 2021 08:05 ET | ExCellThera
MONTRÉAL, Nov. 29, 2021 (GLOBE NEWSWIRE) -- ExCellThera Inc., a clinical-stage cell expansion and engineering company delivering molecules and bioengineering solutions to expand and engineer...
ExCellThera_RGB.png
ExCellThera and Astellas enter into a license for the use of molecule UM171 in the field of pluripotent stem cells
July 13, 2021 08:05 ET | ExCellThera
MONTREAL, July 13, 2021 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a clinical-stage molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune...